Merck & Co and Takeda are in line for exits when drug developer NGM Biopharmaceuticals lists on the Nasdaq Global Select Market.

ASR Insurances and KLP are among the limited partners in Forbion IV, which will invest in biopharmaceutical companies across Europe and North America.

GM&C Life Sciences Fund has stumped up an unspecified sum for Manchester digital health app spinout Clin-e-cal, which creates apps focused on respiratory conditions.

Hong Ma, professor of biology, has been appointed associate dean for research and innovation at Penn State’s Eberly College of Science.

Medical diagnostics developer Drawbridge Health has secured capital from Kyoto University Innovation Capital thanks to a meeting at the GUV: Fusion conference.

Laboratory services supplier Bellen Chemistry has followed a Legend Capital-backed round last year by raising a nine-figure renminbi sum.

Existing investor Takeda Ventures was among the participants in a round that valued the cancer therapy developer at approximately $100m.

Brian Gallagher, Jr has left SR One after eight years as a partner, setting up a Boston office on the way, to join Abingworth.

Cancer biosimilar developer JHL Biotech raised an undisclosed sum in a Sanofi-backed round as it prepares to re-list on a stock exchange, this time choosing Hong Kong.

Lilly Asia Ventures and existing backer Alexandria Real Estate Equities helped the cancer immunotherapy developer add $80m to the $76m it closed last year.